Combination of amino acid solution and a gelatin derivative for inhibiting renal up-take

• US 8,293,873 B2
• Filed: 05/31/2007
• Issued: 10/23/2012
• Est. Priority Date: 05/31/2006
• Status: Active Grant

• Current Assignee: Advanced Accelerator Applications USA, Inc (Novartis Ag)
• Original Assignee: Biosynthema, Inc. (Novartis Ag)
• Inventors: De Jong, Marion, Krenning, Eric P., Rolleman, Edgar
• Primary Examiner(s): NOAKES, SUZANNE MARIE
• Application Number:
  US12/303,090
• Publication Number:
  US 20090318330A1
• Time in Patent Office: 1,972 Days
• Field of Search: None
• US Class Current: 530/354
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/197 the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid carnitine A61K31/205
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 38/014 from connective tissue peptides, e.g. gelatin, collagen
• CPC Class Codes: A61P 13/12 of the kidneys

Abstract

The invention relates to a combination of a solution of a gelatin derivative and at least one amino acid, if desired in the form of a pharmaceutically acceptable salt or carboxylic acid derivative, for inhibiting renal uptake of substances, that are potentially damaging for the kidneys, in a living being.

Claims

1. A therapeutic composition for the inhibition of renal uptake of substances that are potentially damaging for the kidneys and that are used for therapeutic or diagnostic purposes in a living being, comprising:

a solution of a gelatin derivative;

at least one amino acid; and

at least one of a pharmaceutically acceptable excipient, carrier, diluent, and combinations thereof.

2. The composition of claim 1, wherein the composition includes a first quantity of the first amino acid in a range of about 150 milligrams to about 700 milligrams per kilogram body weight of a living being, and a second quantity of the gelatin derivative in a range of about 50 milligrams to about 250 milligrams per kilogram body weight of a living being.

3. The composition of claim 1, wherein the first amino acid is a lysine selected from the group consisting of D-lysine, L-lysine and polylysine.

4. The composition of claim 1, wherein the first amino acid is a lysine, wherein the composition further comprises a second amino acid selected from the group consisting of arginine and ornithine.

24. The composition of claim 1, wherein the gelatin derivative is a gelatin-based plasma expander.

5. A method of preparing a composition for inhibiting renal uptake of a substance in a living being, comprising:

combining a solution of a gelatin derivative with at least one amino acid.

6. The method of claim 5, wherein the at least one amino acid is in the form of a pharmaceutically acceptable salt or carboxylic acid derivative.

7. The method of claim 5, wherein the at least one amino acid is a lysine selected from the group consisting of D-lysine, L-lysine, and polylysine.

8. The method of claim 5, wherein the at least one amino acid is a mixture of a lysine and a second amino acid selected from the group consisting of arginine and ornithine.

9. The method of claim 5, wherein the gelatin derivative is a gelatin-based plasma expander.

10. The method of claim 9, wherein the gelatin-based plasma expander is GELOFUSINE®

.

11. The method of claim 5, wherein the gelatin derivative is a synthetic colloidal solution of urea cross-linked degraded gelatin.

12. The method of claim 11, wherein the synthetic colloidal solution of urea cross-linked degraded gelatin is HAEMACCEL®

.

13. The method of claim 5, wherein the composition includes a first quantity of the at least one amino acid in a range of about 150 milligrams to about 700 milligrams per kilogram body weight of the living being, and a second quantity of the gelatin derivative in a range of about 50 milligrams to about 250 milligrams per kilogram body weight of the living being.

14. The method of claim 5, further comprising combining at least one of a pharmaceutically acceptable excipient, carrier, diluent, and combinations thereof with the combination of the solution of the gelatin derivative and the at least one amino acid.

15. A method of inhibiting renal uptake of a substance in a living being, comprising:

preparing a composition, wherein the composition includes;

a solution of a gelatin derivative; and

a first amino acid, wherein the first amino acid is in the form of a pharmaceutically acceptable salt or carboxylic acid derivative; and

administering the composition to the living being.

16. The method of claim 15, wherein the first amino acid is a lysine selected from the group consisting of D-lysine, L-lysine and polylysine.

17. The method of claim 15, wherein the first amino acid is a lysine, wherein the composition further comprises a second amino acid selected from the group consisting of arginine and ornithine.

18. The method of claim 15, wherein the gelatin derivative is a gelatin-based plasma expander.

19. The method of claim 18, wherein the gelatin-based plasma expander is GELOFUSINE®

.

20. The method of claim 15, wherein the gelatin derivative is a synthetic colloidal solution of urea cross-linked degraded gelatin.

21. The method of claim 20, wherein the synthetic colloidal solution of urea cross-linked degraded gelatin is HAEMACCEL®

.

22. The method of claim 15, wherein the composition includes a first quantity of the first amino acid in a range of about 150 milligrams to about 700 milligrams per kilogram body weight of the living being, and a second quantity of the gelatin derivative in a range of about 50 milligrams to about 250 milligrams per kilogram body weight of the living being.

23. The method of claim 15, wherein the composition further comprises at least one of a pharmaceutically acceptable excipient, carrier, diluent, and combinations thereof.